Inhibrx reported a reduced net loss in Q3 2025 compared to the prior year, driven by lower operating expenses. The company advanced its ozekibart program with positive trial results, positioning it for a potential BLA submission in Q2 2026.
Positive topline results from registrational trial of ozekibart (INBRX-109) in chondrosarcoma met primary endpoint.
positiveNet loss decreased to $35.3 million in Q3 2025 from $43.9 million in Q3 2024.
positiveResearch and development expenses decreased to $28.5 million from $38.9 million YoY.
positiveGeneral and administrative expenses decreased to $5.3 million from $7.9 million YoY.
positiveThe company reported a net loss of $35.3 million for the quarter.
negativeCash and cash equivalents decreased to $153.1 million from $186.6 million in the prior quarter.
attentionOther expense was $1.4 million, compared to other income of $2.9 million in the prior year, due to increased interest expense on outstanding debt.
attentionMargin metrics will be available once backend extracts data from insights_json
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Positive topline results from the registrational trial of ozekibart (INBRX-109) in chondrosarcoma were announced.
Ozekibart met its primary endpoint in chondrosarcoma, demonstrating statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo.
Interim data from expansion cohorts in colorectal cancer and Ewing sarcoma demonstrate high response and disease control rates.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.